Investigational Medicinal Products - Recent Changes in EC Guidance
Recommendation
28/29 April 2026
From QbD to Process Validation
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
As we reported before in our IMPs: Four new public consultations concerning GMP and GCP published the implementation of the Clinical Trial Regulation 536/2014 resulted in four new public consultations concerning good manufacturing practices and clinical trials for human medicinal products (opened August 28, 2015) with closing date November 24, 2015.
As a consequence Annex 13 is expected to be deleted from EudraLex Vol 4 when the new guidelines "Detailed Commission guidelines on GMP for IMPs for human use" become operational. It carries over relevant principles of Annex 13.
Basically the ideas are the same. However there is more detail in regard of
- the pharmaceutical quality system and handling deviations by CAPA
- supplier approval
- quality risk management principles
- final certifying by the qualified person
- the retaining period of batch records
- reference and retention samples.
On the European QP Assocaition website you can find a Synopsis of Annex 13 / "Detailed Commision guidelines for GMP for IMPs for human use". There you will also find a summary which contains links to the most recent changes being published for consultation.
Related GMP News
16.04.2026EMA Guidance on Conducting Clinical Trials during Public Health Emergencies
16.04.2026EMA accelerates Development of Medicines
16.04.2026What are the GMP Requirements for Drug Development?
26.03.2026FDA Guidance on Statistical Methods for Clinical Trials
26.03.2026Final ICH M11 CeSHarP Guideline
24.02.2026Good AI Practice in Drug Development